UK’s NICE Recommends Xgeva for Skeletal Events From Most Bone Metastases

Drug Industry Daily
The UK’s National Institute for Health and Clinical Excellence (NICE) is recommending Amgen’s Xgeva for skeletal-related events associated with with bone metastases from breast cancer and other solid cancer tumors in patients who would have been prescribed bisphosphonates.

To View This Article:


Subscribe To Drug Industry Daily